Item 8.01 Other Events

On May 14, 2020, the Company determined that it will not be able to file its Form 10-Q for the quarter ended March 31, 2020 on time as a result of factors relating to the COVID-19 pandemic and the steps taken by states to seek to reduce the spread of the virus by either requesting or requiring businesses to close or work remotely. As a result, the Company's accounting staff, which is working on a reduced staff basis from home, was not able to complete the financial statements for either period in a timely manner in order to file the Form 10-Q by the required date, after giving effect to the extension permitted by Section 12b-25. The Company is filing this report on Form 8-K to report that it will rely on the exemption from timely filing provided by the SEC in Release No. 34-88318, dated March 4, 2020, as modified by Release No. 34-88465, dated March 25, 2020 (the "Release"). The Company anticipates that it will file the Form 10-Q no later than 45 days from the date the report is due, which is July 2, 2020.

As previously reported, on December 19, 2019, the Company acquired all of the outstanding capital stock of JAS Practice Management, Inc., a Texas corporation doing business as JAS Consulting, Inc. ("JAS") from Justin Anderson and Stacey Anderson. Justin Anderson is the Company's sole director and chief executive officer and Stacey Anderson is his spouse. Because JAS is a related party, under generally accepted accounting principles, the historical financial statements of the Company prior to December 19, 2019 will reflect the business of JAS and not the historical information of the Company as previously reported in its SEC filings. As a result, the Company's financial statements for the three months ended March 31, 2019 will be the financial statements of JAS rather than the financial statements that were previously filed with the SEC. The historical financial information concerning the Company for the three months ended March 31, 2019 will be reflected in the notes to the consolidated financial statements.

As of the date of this report, the Company does not have estimated results of operations for the three months ended March 31, 2020 or 2019.

Effect of COVID-19 on our Business

Our present business is primarily the marketing and sale of the COVID-19 test kits, which we are marketing pursuant our distribution agreements with Co-Diagnostics Inc. which we entered into in March 2020. The COVID-19 pandemic and the response to the pandemic is affecting our business in a number of ways, including, but not limited to, the following.





    ·   Sales of medical products and services have declined dramatically as
        medical practices have closed or substantially reduced their operations,
        with the result that they do not require either products or supplies from
        us.

    ·   Our suppliers have substantially reduced, if not closed, their business,
        with no assurance that they will be either willing or able to provide us
        with products after the economic slowdown ceases.

    ·   Our suppliers may not continue in business and we may not be able to
        develop alternative sources of supply.

    ·   We are incurring additional operating expenses without offsetting revenue.

    ·   Those medical practices that engaged us for services or purchased products
        from us may find other sources of products and services or may not operate
        as independent medical practices.




    ·   Our reliance on Co-Diagnostics for the test kits and the ability and
        willingness of Co-Diagnostics to fill our orders in a timely manner and to
        continue our agreements in effect since the agreements can be terminated
        by either party at any time.

    ·   Because steps taken by states to reduce the spread of COVID-19, our
        employees are working from home and using their personal computer, which
        could result is security breaches with respect to information maintained
        by us.

    ·   Our ability to obtain on reasonable terms the viral RNA extractions and
        qPCR equipment in view of the worldwide demand for such products, with any
        failure to obtain the viral RNA extractions and qPCR equipment impairing
        our ability to sell the Co-Diagnostics test kits..

    ·   Our ability to sell Co-Diagnostics test kits.

    ·   Our ability to raise financing for our operations may be affected by both
        the willingness and ability of potential financing sources to invest in an
        undercapitalized business, particularly at a time when the potential
        financing source may need to devote its resources to existing portfolio
        companies which may be in need of financing.

    ·   Although COVID-19 test businesses might seem to be attractive to
        investors, until and unless we generate sufficient revenue and cash flow
        from our COVID-19 test business to demonstrate to investors that we have a
        meaningful and continuing COVID-19 test business, particularly in view of
        the SEC's action to suspend trading in our common stock, it will be
        difficult for us to raise funds for our business.





2

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2020 PreCheck Health Services, Inc.



                   By:  /s/ Douglas Samuelson
                        Douglas Samuelson
                        Chief Financial Officer





3

© Edgar Online, source Glimpses